Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 1/20 | 0.49 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.49 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.37 |
| ▸ | BRD4 | O60885 | 1/20 | 0.37 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.37 |
| ▸ | IDH1 | O75874 | 1/20 | 0.36 |
| ▸ | FAAH | O00519 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31181154 | 1.00 | MTNR1A (0.49) | MTNR1AMTNR1BEPHX2MAPTGAA | |
| Trifluoroacetic Acid SCHEMBL30965226 | 0.90 | EPHX2 (0.43) | MTNR1AMTNR1BEPHX2MAPTGAA | |
| SCHEMBL8562595 | 0.84 | GAA (0.54) | MTNR1AMTNR1BEPHX2MAPTGAA | |
| SCHEMBL30288898 | 0.84 | GAA (0.54) | MTNR1AMTNR1BEPHX2MAPTGAA | |
| SCHEMBL924219 | 0.84 | GAA (0.54) | MTNR1AMTNR1BEPHX2MAPTGAA | |
| SCHEMBL29463686 | 0.84 | GAA (0.54) | MTNR1AMTNR1BEPHX2MAPTGAA | |
| SCHEMBL28038780 | 0.84 | GAA (0.54) | MTNR1AMTNR1BEPHX2MAPTGAA | |
| SCHEMBL6220479 | 0.83 | PTK2B (0.41) | MTNR1AMTNR1BEPHX2MAPTIDH1 | |
| SCHEMBL8562033 | 0.83 | MTNR1A (0.56) | MTNR1AMTNR1BEPHX2MAPTGAA | |
| SCHEMBL8562039 | 0.83 | MTNR1A (0.56) | MTNR1AMTNR1BEPHX2MAPTGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119585247-A | Bicyclic heterocyclic amide inhibitors of nav1.8 for the treatment of pain | 赛特温治疗公司 | 2025-03-07 | — | — | CN | disclosed |
| US-20230399304-A1 | COVALENT INHIBITORS OF CREATINE KINASE (CK) AND USES THEREOF FOR TREATING AND PREVENTING CANCER | DANA-FARBER CANCER INSTITUTE, INC. | 2023-12-14 | — | — | US | disclosed |
| US-20230399304-A1 | COVALENT INHIBITORS OF CREATINE KINASE (CK) AND USES THEREOF FOR TREATING AND PREVENTING CANCER | DANA-FARBER CANCER INSTITUTE, INC. | 2023-12-14 | — | — | US | disclosed |
| WO-2022087433-A1 | COVALENT INHIBITORS OF CREATINE KINASE (CK) AND USES THEREOF FOR TREATING AND PREVENTING CANCER | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-04-28 | — | — | WO | disclosed |
| WO-2021031071-A1 | AMIDE DERIVATIVE AND USE THEREOF IN MEDICINE | 广东东阳光药业有限公司 | 2021-02-25 | — | — | WO | disclosed |
| CN-105814040-B | The condensed 1,4- dihydro two of inhibitor as thermal excited transcryption factor 1 dislikes ene derivative | 癌症研究科技有限公司 | 2019-07-30 | — | — | CN | disclosed |
| CN-105051013-A | Laquinimod sodium crystals and improved process for their manufacture | TEVA PHARMA | 2015-11-11 | — | — | CN | disclosed |
| EP-1560827-A1 | ANTI-INFECTIVE AGENTS | Abbott Laboratories (US) | 2005-08-10 | — | — | EP | disclosed |
| WO-2004041818-A1 | ANTI-INFECTIVE AGENTS | ABBOTT LABORATORIES (US) | 2004-05-21 | — | — | WO | disclosed |
| CN-1132818-C | 4-oxo-1, 4-dihydro-3-quinolinecarboxamides as antiviral agents | PHARMACIA & UPJOHN CO. (US) | 2003-12-31 | — | — | CN | disclosed |
| US-5594005-A | Use of quinoline-3-carboxamide compounds for treatment of diabetes | PHARMACIA AB (SE) | 1997-01-14 | — | — | US | disclosed |
| EP-0751772-A1 | NEW USE OF QUINOLINE-3-CARBOXAMIDE COMPOUNDS | Pharmacia & Upjohn Aktiebolag (SE) | 1997-01-08 | — | — | EP | disclosed |
| EP-0749310-A1 | NEW USE OF QUINOLINE-3-CARBOXAMIDE COMPOUNDS | Pharmacia & Upjohn Aktiebolag (SE) | 1996-12-27 | — | — | EP | disclosed |
| EP-0711165-A1 | USE OF QUINOLINE-3-CARBOXAMIDE COMPOUNDS FOR INHIBITING THE PRODUCTION OF TUMOUR NECROSIS FACTOR (TNF) AND/OR FOR THE TREATMENT OF SEPTIC SHOCK | Pharmacia & Upjohn Aktiebolag (SE) | 1996-05-15 | — | — | EP | disclosed |
| WO-1995024196-A1 | NEW USE OF QUINOLINE-3-CARBOXAMIDE COMPOUNDS | PHARMACIA & UPJOHN AB (SE) | 1995-09-14 | — | — | WO | disclosed |
| WO-1995024195-A1 | NEW USE OF QUINOLINE-3-CARBOXAMIDE COMPOUNDS | PHARMACIA & UPJOHN AB (SE) | 1995-09-14 | — | — | WO | disclosed |
| WO-1995003051-A1 | USE OF QUINOLINE-3-CARBOXAMIDE COMPOUNDS FOR INHIBITING THE PRODUCTION OF TUMOUR NECROSIS FACTOR (TNF) AND/OR FOR THE TREATMENT OF SEPTIC SHOCK | PHARMACIA AB (SE) | 1995-02-02 | — | — | WO | disclosed |
| EP-0634931-A1 | THE USE OF QUINOLINE-3-CARBOXAMIDE COMPOUNDS FOR TREATMENT OF DIABETES | Pharmacia & Upjohn Aktiebolag (SE) | 1995-01-25 | — | — | EP | disclosed |
| WO-1993019756-A9 | THE USE OF QUINOLINE-3-CARBOXAMIDE COMPOUNDS FOR TREATMENT OF DIABETES | — | 1994-10-27 | — | — | WO | disclosed |
| WO-1993019756-A1 | THE USE OF QUINOLINE-3-CARBOXAMIDE COMPOUNDS FOR TREATMENT OF DIABETES | KABI PHARMACIA AB (SE) | 1993-10-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230399304-A1 | COVALENT INHIBITORS OF CREATINE KINASE (CK) AND USES THEREOF FOR TREATING AND PREVENTING CANCER | CKMT1A; CKMT1B, PHKG1, PCK1 | MTNR1A 2477/4885MTNR1B 2875/4885EPHX2 3577/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.